Aliases & Classifications for Plague

MalaCards integrated aliases for Plague:

Name: Plague 12 56 41 3 14 69
Yersiniosis 56 3
Yersinia Infections 69

Characteristics:

Orphanet epidemiological data:

56
plague
Prevalence: 1-9/100000 (Europe); Age of onset: All ages;

Classifications:

Orphanet: 56  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:3482
ICD10 33 A20 A20.9
ICD9CM 35 020 020.9
MeSH 42 D010930
NCIt 47 C85015
Orphanet 56 ORPHA707
MESH via Orphanet 43 D010930 D015009
UMLS via Orphanet 70 C0032064 C0043407
ICD10 via Orphanet 34 A20.0 A20.1 A20.2 more
UMLS 69 C0032064

Summaries for Plague

MedlinePlus : 41 plague is an infection caused by the bacterium yersinia pestis. the bacteria are found mainly in rats and in the fleas that feed on them. people and other animals can get plague from rat or flea bites. in the past, plague destroyed entire civilizations. today plague is uncommon, due to better living conditions and antibiotics. there are three forms of plague: bubonic plague causes the tonsils, adenoids, spleen, and thymus to become inflamed. symptoms include fever, aches, chills, and tender lymph glands. in septicemic plague, bacteria multiply in the blood. it causes fever, chills, shock, and bleeding under the skin or other organs. pneumonic plague is the most serious form. bacteria enter the lungs and cause pneumonia. people with the infection can spread this form to others. this type could be a bioterror agent. lab tests can diagnose plague. treatment is a strong antibiotic. there is no vaccine. nih: national institute of allergy and infectious diseases

MalaCards based summary : Plague, also known as yersiniosis, is related to pneumonic plague and bubonic plague, and has symptoms including fever and pruritus. An important gene associated with Plague is CCR5 (C-C Motif Chemokine Receptor 5 (Gene/Pseudogene)), and among its related pathways/superpathways are Influenza A and NF-kappaB Signaling. The drugs Anticholesteremic Agents and Antimetabolites have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and spleen, and related phenotypes are cellular and cardiovascular system

Disease Ontology : 12 A primary bacterial infectious disease that results_in infection, located in lymph node, located in vasculature or located in lungs, has material basis in Yersinia pestis, which is transmitted_by oriental rat flea (Xenopsylla cheopis) infected by feeding on rodents and other mammals, transmitted_by air, transmitted_by direct contact or transmitted_by ingestion of contaminated undercooked food.

CDC : 3 Plague is a disease that affects humans and other mammals. It is caused by the bacterium, Yersinia pestis. Humans usually get plague after being bitten by a rodent flea that is carrying the plague bacterium or by handling an animal infected with plague. Plague is infamous for killing millions of people in Europe during the Middle Ages. Today, modern antibiotics are effective in treating plague. Without prompt treatment, the disease can cause serious illness or death. Presently, human plague infections continue to occur in the western United States, but significantly more cases occur in parts of Africa and Asia.

Related Diseases for Plague

Diseases related to Plague via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 66)
id Related Disease Score Top Affiliating Genes
1 pneumonic plague 12.4
2 bubonic plague 12.4
3 septicemic plague 12.3
4 tularemia 11.2
5 pestis minor 10.9
6 anthrax disease 10.8
7 punctate palmoplantar keratoderma type 2 10.3 PECAM1 TYMP
8 waterhouse-friderichsen syndrome 10.3 PECAM1 SELE
9 partial central choroid dystrophy 10.2 PECAM1 SELE
10 angiokeratoma 10.2 CCR5 TLR9
11 bobble-head doll syndrome 10.2 MYD88 PECAM1
12 hypervitaminosis d 10.1 CCR5 MYD88 TLR9
13 septic myocarditis 10.1 CCR5 PLG
14 hereditary choroidal atrophy 10.1 CD86 MYD88 TLR9
15 spinal polio 10.0 CD83 CD86
16 cellulitis 10.0 MYD88 PLG
17 diamond-blackfan anemia 1 10.0 MYD88 SELE TLR9
18 tuberculosis 10.0
19 carotid artery dissection 10.0 CCR5 DDX58 TLR9
20 hemi 3 syndrome 10.0 PECAM1 PLG
21 cholera 9.9
22 goodpasture syndrome 9.9 CCR5 SELE TLR9
23 perineurioma 9.9 PLG SELE
24 colorectal adenoma 9.8 PLG TYMP
25 ecthyma 9.8
26 typhoid fever 9.8
27 pneumonia 9.8
28 influenza 9.8
29 smallpox 9.8
30 advanced sleep phase syndrome, familial, 1 9.7 CCR5 CD86 TLR9
31 malaria 9.7
32 legionnaire disease 9.7
33 legionnaires' disease 9.7
34 relapsing fever 9.7
35 measles 9.7
36 leprosy 9.6
37 keratitis 9.6
38 hiv-1 9.6
39 hemochromatosis 9.6
40 scurvy 9.6
41 crohn's disease 9.6
42 hepatitis 9.6
43 laryngotracheitis 9.6
44 swine influenza 9.6
45 mucositis 9.6
46 thrombotic thrombocytopenic purpura 9.6
47 q fever 9.6
48 bartonellosis 9.6
49 dysentery 9.6
50 blastomycosis 9.6

Graphical network of the top 20 diseases related to Plague:



Diseases related to Plague

Symptoms & Phenotypes for Plague

UMLS symptoms related to Plague:


fever, pruritus

MGI Mouse Phenotypes related to Plague:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.11 CCR5 CD86 CDC25C DDX58 MGAT1 MYD88
2 cardiovascular system MP:0005385 9.95 SELE CCR5 MGAT1 MYD88 PECAM1 PLG
3 digestive/alimentary MP:0005381 9.92 CCR5 CDC25C DDX58 MYD88 PECAM1 PLG
4 hematopoietic system MP:0005397 9.85 CCR5 CD83 CD86 DDX58 MGAT1 MYD88
5 endocrine/exocrine gland MP:0005379 9.8 CD83 CD86 CDC25C MGAT1 MYD88 PLG
6 homeostasis/metabolism MP:0005376 9.7 TLR9 TYMP CCR5 CD86 DDX58 MGAT1
7 immune system MP:0005387 9.32 CCR5 CD83 CD86 DDX58 MYD88 PECAM1

Drugs & Therapeutics for Plague

Drugs for Plague (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 161)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Anticholesteremic Agents Phase 4
2 Antimetabolites Phase 4,Phase 3,Phase 2,Early Phase 1
3 Calcium, Dietary Phase 4,Phase 3
4 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2
5 Hypolipidemic Agents Phase 4
6 Lipid Regulating Agents Phase 4
7 Rosuvastatin Calcium Phase 4 147098-20-2
8 Adjuvants, Immunologic Phase 4,Phase 3,Phase 1
9 Aluminum phosphate Phase 4
10 Antacids Phase 4,Phase 1
11 Anti-Ulcer Agents Phase 4,Phase 1
12 Gastrointestinal Agents Phase 4,Phase 3,Phase 1
13 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
14
Streptomycin Approved, Vet_approved Phase 2, Phase 3 57-92-1 19649
15
Dimethyl sulfoxide Approved, Vet_approved Phase 3 67-68-5 679
16
Etanercept Approved, Investigational Phase 3 185243-69-0
17
Morphine Approved, Investigational Phase 3 57-27-2 5288826
18
Interferon beta-1a Approved, Investigational Phase 3 145258-61-3 6438354
19
Interferon beta-1b Approved Phase 3 145155-23-3
20
Apremilast Approved, Investigational Phase 3 608141-41-9 11561674
21
Crizotinib Approved Phase 3,Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
22
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 446556 60843
23
Epinephrine Approved, Vet_approved Phase 2, Phase 3 51-43-4 5816
24 Racepinephrine Approved Phase 2, Phase 3
25
Benzocaine Approved Phase 3 1994-09-7, 94-09-7 2337
26
Cytarabine Approved, Investigational Phase 3,Early Phase 1 147-94-4 6253
27
Etoposide Approved Phase 3,Phase 1,Phase 2,Early Phase 1 33419-42-0 36462
28
Methotrexate Approved Phase 3,Phase 2,Early Phase 1 1959-05-2, 59-05-2 126941
29
Hydrocortisone Approved, Vet_approved Phase 2, Phase 3 50-23-7 5754 657311
30
Budesonide Approved Phase 3 51333-22-3 63006 5281004
31
Rivaroxaban Approved Phase 3 366789-02-8
32
rituximab Approved Phase 3 174722-31-7 10201696
33 Vedolizumab Approved Phase 3 943609-66-3
34
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
35
Thrombin Approved Phase 3
36
Pregabalin Approved, Illicit, Investigational Phase 3 148553-50-8 5486971
37
Dimethyl fumarate Approved, Investigational Phase 3 624-49-7 5271565 637568
38
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
39
Idarubicin Approved Phase 3 58957-92-9 42890
40
Lenograstim Approved Phase 3 135968-09-1
41
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
42
Adalimumab Approved Phase 3 331731-18-1 16219006
43
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
44
Ofloxacin Approved Phase 3 82419-36-1 4583
45
Xylometazoline Approved Phase 3 526-36-3 5709
46
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Early Phase 1 59-30-3 6037
47
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Early Phase 1 58-05-9 143 6006
48 tannic acid Approved, Nutraceutical Phase 3
49
Docetaxel Approved May 1996, Investigational Phase 3 114977-28-5 148124 9877265
50
Butyric Acid Experimental Phase 2, Phase 3 107-92-6 264

Interventional clinical trials:

(show top 50) (show all 98)

id Name Status NCT ID Phase Drugs
1 Resuvastatin Treatment for Symptomatic Middle Cerebral Artery Stenosis Based on High-resolution Magnetic Resonance Imaging Unknown status NCT02041117 Phase 4 Rosuvastatin
2 Tolerability and Immunogenicity Study of Fluval AB Influenza Vaccine in Adults and Elderly Persons Completed NCT01404182 Phase 4
3 Evaluation of Long-term Prucalopride Treatment With Chronic Constipation in Subjects Aged ≥ 18 Years Completed NCT01424228 Phase 4 placebo;prucalopride
4 School Inner-City Asthma Intervention Study (SICAS-2) Recruiting NCT02291302 Phase 4
5 EASY: Extended Access to Sollpura Over Years Recruiting NCT02823964 Phase 4 Liprotamase
6 Treatment and Diagnosis of Plague Completed NCT00128466 Phase 2, Phase 3 gentamicin;streptomycin
7 Mouse Allergen and Asthma Intervention Trial Completed NCT01251224 Phase 3
8 A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension Completed NCT00644605 Phase 3 sildenafil;sildenafil;placebo;sildenafil
9 SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis Completed NCT02279498 Phase 3 Liprotamase;porcine (pig) PERT
10 Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy Completed NCT00676507 Phase 3
11 Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects Completed NCT02378506 Phase 3
12 Phase 3 Study of RPC1063 in Relapsing MS Completed NCT02294058 Phase 3 RPC1063;Beta interferon
13 Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study) Completed NCT02047734 Phase 3 RPC1063 0.5 mg;RPC1063 1 mg;RPC1063 placebo;Interferon β-1a;IFN β-1a placebo
14 PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Completed NCT01212757 Phase 3 Apremilast 20mg;Apremilast 30mg;Placebo + 20 mg Apremilast;Placebo + 30 mg Apremilast
15 Study Evaluating Persistence of Anti-HBs Antibodies in Uraemic Patients Receiving Henogen's HBV Vaccine, or Fendrix™ Completed NCT00445185 Phase 3
16 A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to GSK Biologicals Adjuvanted Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Have Not Been Exposed to Hepatitis B. Completed NCT00291941 Phase 3
17 An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene Completed NCT00932893 Phase 3 PF-02341066;Pemetrexed;Docetaxel
18 Hydrocortisone Treatment In Systemic Low Blood Pressure During Hypothermia in Asphyxiated Newborns Recruiting NCT02700828 Phase 2, Phase 3 Hydrocortisone;Placebo
19 Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) Recruiting NCT02465567 Phase 3 BGF MDI 320/14.4/9.6 μg;GFF MDI 14.4/9.6 μg;BGF MDI 160/14.4/9.6 μg;BFF MDI 320/9.6 μg
20 A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients Recruiting NCT02111564 Phase 3 Rivaroxaban, 10 mg;Rivaroxaban, 7.5 mg;Placebo
21 Study to Assess if ABP798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Rituximab Recruiting NCT02792699 Phase 3 ABP 798;Rituximab
22 RESULT: Reliable, Emergent Solution Using Liprotamase Treatment Recruiting NCT03051490 Phase 3 Liprotamase;porcine PERT
23 A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s) Recruiting NCT03162796 Phase 3 Guselkumab;Placebo
24 A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD) Recruiting NCT03114657 Phase 3 Crenezumab;Placebo
25 Vedolizumab Subcutaneous Long-Term Open-Label Extension Study Recruiting NCT02620046 Phase 3 Vedolizumab SC
26 Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease Recruiting NCT02611817 Phase 3 Vedolizumab SC 108;Placebo SC;Vedolizumab IV 300 mg
27 A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations Recruiting NCT02413580 Phase 3
28 Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 Recruiting NCT02403323 Phase 3 etrolizumab
29 A Study of the Safety and Efficacy of Etrolizumab in Patients With Moderately to Severely Active Crohn's Disease Recruiting NCT02394028 Phase 3 Etrolizumab 210 mg;Etrolizumab 105 mg;Placebo
30 A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors Recruiting NCT02165215 Phase 3 Etrolizumab;Placebo
31 Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies Recruiting NCT02118584 Phase 3 Etrolizumab
32 A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Are Refractory to or Intolerant of Tumor Necrosis Factor (TNF) Inhibitors Recruiting NCT02100696 Phase 3 Etrozulimab;Placebo
33 Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS) Recruiting NCT02239120 Phase 3 optional ASA as comedication;placebo to ASA;placebo to optional ASA as comedication;placebo to dabigatran etexilate;ASA 100 mg;dabigatran etexilate
34 A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures. Recruiting NCT01747915 Phase 3 Pregabalin Dose Level 1;Pregabalin Dose Level 2;Placebo
35 A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clon Recruiting NCT01463306 Phase 3 Pregabalin
36 Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®) Recruiting NCT02907177 Phase 3 Ponesimod
37 (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive Active, not recruiting NCT02039726 Phase 3 Quizartinib;Salvage Chemotherapy
38 Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis Active, not recruiting NCT02611830 Phase 3 Vedolizumab IV 300 mg;Placebo IV;Vedolizumab SC 108 mg;Placebo SC
39 Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis Active, not recruiting NCT01583374 Phase 3 Apremilast tablet 20 mg;Apremilast tablet 30 mg BID;Placebo
40 Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA) Active, not recruiting NCT01307423 Phase 3 Apremilast 20mg;Apremilast 30mg;Placebo
41 A Study Comparing ABT-494 Monotherapy to Methotrexate (MTX) Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY) Active, not recruiting NCT02706951 Phase 3 ABT-494;Methotrexate;ABT-494 matching placebo;Methotrexate matching placebo
42 A Study to Compare ABT-494 Monotherapy to Methotrexate Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate Active, not recruiting NCT02706873 Phase 3 ABT-494;Methotrexate;ABT-494 matching placebo;Methotrexate matching placebo
43 A Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate Active, not recruiting NCT02629159 Phase 3 ABT-494;Placebo for ABT-494;Adalimumab;Placebo for Adalimumab
44 Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections Active, not recruiting NCT01978938 Phase 3 Eravacycline;Levofloxacin
45 A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis Enrolling by invitation NCT02576717 Phase 3 RPC1063
46 VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome Terminated NCT01130246 Phase 3 A-002, varespladib methyl;Placebo
47 A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC Terminated NCT01798485 Phase 3 Docetaxel;Ganetespib
48 The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects Terminated NCT01975389 Phase 3 bococizumab (PF-04950615);Placebo
49 The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects Terminated NCT01975376 Phase 3 bococizumab (PF-04950615);Placebo
50 A Clinical Trial to Evaluate the Safety and Efficacy of Ciprofloxacin in the Treatment of Plague in Humans Unknown status NCT01243437 Phase 2 ciprofloxacin;doxyxcycline

Search NIH Clinical Center for Plague

Genetic Tests for Plague

Anatomical Context for Plague

MalaCards organs/tissues related to Plague:

39
Lung, Testes, Spleen, Lymph Node, Skin, Thymus, Tonsil

Publications for Plague

Articles related to Plague:

(show top 50) (show all 892)
id Title Authors Year
1
Vaccines for Conservation: Plague, Prairie Dogs & Black-Footed Ferrets as a Case Study. ( 28879613 )
2017
2
Resistance to the crayfish plague, Aphanomyces astaci (Oomycota) in the endangered freshwater crayfish species, Austropotamobius pallipes. ( 28750039 )
2017
3
Plenty Is No Plague: Streptomyces Symbiosis with Crops. ( 27916552 )
2017
4
Characterization of duck plague virus stability at extreme conditions of temperature, pH and salt concentration. ( 27746073 )
2017
5
Enhanced Macrophage M1 Polarization and Resistance to Apoptosis Enable Resistance to Plague. ( 28934426 )
2017
6
Small-Scale Die-Offs in Woodrats Support Long-Term Maintenance of Plague in the U.S. Southwest. ( 28792853 )
2017
7
Patterns of Human Plague in Uganda, 2008-2016. ( 28820134 )
2017
8
Zinc transporters YbtX and ZnuABC are required for the virulence of Yersinia pestis in bubonic and pneumonic plague in mice. ( 28540946 )
2017
9
Eight Whole-Genome Assemblies of Yersinia pestis subsp. microtus bv. caucasica Isolated from the Common Vole (Microtus arvalis) Plague Focus in Dagestan, Russia. ( 28839028 )
2017
10
A polymerase chain reaction assay for detection of virulent and attenuated strains of duck plague virus. ( 28860100 )
2017
11
Reorganizing Hospital Space: The 1894 Plague Epidemic in Hong Kong and the Germ Theory. ( 28814702 )
2017
12
Model-based analysis of an outbreak of bubonic plague in Cairo in 1801. ( 28637916 )
2017
13
Serological and PCR investigation of Yersinia pestis in potential reservoir hosts from a plague outbreak focus in Zambia. ( 28754138 )
2017
14
A Historical View of Motion Sickness-A Plague at Sea and on Land, Also with Military Impact. ( 28421029 )
2017
15
Protein abundances can distinguish between naturally-occurring and laboratory strains of Yersinia pestis, the causative agent of plague. ( 28854255 )
2017
16
Statistics Commentary Series: Commentary No. 23: A Plague of Decimals: Why Too Much Precision Can be Misleading. ( 28926350 )
2017
17
The Live Chicken Treatment for Buboes: Trying a Plague Cure in Medieval and Early Modern Europe. ( 28757495 )
2017
18
Yersinia pestis halotolerance illuminates plague reservoirs. ( 28054667 )
2017
19
"Fleaing" the Plague: Adaptations of Yersinia pestis to Its Insect Vector That Lead to Transmission. ( 28886687 )
2017
20
Temporal phylogeography of Yersinia pestis in Madagascar: Insights into the long-term maintenance of plague. ( 28873412 )
2017
21
Pneumonic Plague Transmission, Moramanga, Madagascar, 2015. ( 28221119 )
2017
22
Paleoproteomics of the Dental Pulp: The plague paradigm. ( 28746380 )
2017
23
RNA-seq comparative analysis of Peking ducks spleen gene expressionA 24A h post-infected with duck plague virulent or attenuated virus. ( 28903751 )
2017
24
Temporal and spatial distribution characteristics in the natural plague foci of Chinese Mongolian gerbils based on spatial autocorrelation. ( 28780908 )
2017
25
A Field Study of Plague and Tularemia in Rodents, Western Iran. ( 28165869 )
2017
26
Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague. ( 28220110 )
2017
27
Effects of substrate salinity on oviposition, embryonic development and survival in the Australian plague locust, Chortoicetes terminifera (Walker). ( 27742224 )
2017
28
Plague: A Millenary Infectious Disease Reemerging in the XXI Century. ( 28904964 )
2017
29
Isolation and Suffering Related to Serious and Terminal Illness: Metaphors and Lessons From Albert Camus' Novel, The Plague. ( 28778561 )
2017
30
Knowledge and practices related to plague in an endemic area of Uganda. ( 28935246 )
2017
31
Xenopsylla brasiliensis Fleas in Plague Focus Areas, Madagascar. ( 27513742 )
2016
32
Plague Vaccine Development: Current Research and Future Trends. ( 28018363 )
2016
33
Normal growth, altered growth? Study of the relationship between harris lines and bone form within a post-medieval plague cemetery (Dendermonde, Belgium, 16th Century). ( 27338787 )
2016
34
Oral vaccination against plague using Yersinia pseudotuberculosis. ( 27046452 )
2016
35
Correction: Temporal Progression of Pneumonic Plague in Blood of Nonhuman Primate: A Transcriptomic Analysis. ( 27078634 )
2016
36
Drug Testing and Toxicology: Redefining the Plague of Darkness. ( 27842795 )
2016
37
Multiple antigens of Yersinia pestis delivered by live recombinant attenuated Salmonella vaccine strains elicit protective immunity against plague. ( 27060051 )
2016
38
From plague to MERS: coordinating Australia's response to emerging infectious diseases. ( 27997933 )
2016
39
A Personal View of How Paleomicrobiology Aids Our Understanding of the Role of Lice in Plague Pandemics. ( 27726806 )
2016
40
Plague Vaccines: Status and Future. ( 27722869 )
2016
41
Notes from the Field: Plague in Domestic Cats - Idaho, 2016. ( 27932783 )
2016
42
Adjunctive Corticosteroid Treatment Against Yersinia pestis Improves Bacterial Clearance, Immunopathology, and Survival in the Mouse Model of Bubonic Plague. ( 27402776 )
2016
43
Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague. ( 27745954 )
2016
44
Host transcriptomic responses to pneumonic plague reveal that Yersinia pestis inhibits both the initial adaptive and innate immune responses in mice. ( 27876297 )
2016
45
New Insights into Autoinducer-2 Signaling as a Virulence Regulator in a Mouse Model of Pneumonic Plague. ( 27981238 )
2016
46
Epidemiological analysis of the Eyam plague outbreak of 1665-1666. ( 27170724 )
2016
47
Plague in Iran: past and current situation. ( 27457063 )
2016
48
Cross-Species Antiviral Activity of Goose Interferons against Duck Plague Virus Is Related to Its Positive Self-Feedback Regulation and Subsequent Interferon Stimulated Genes Induction. ( 27438848 )
2016
49
Climatic and evolutionary drivers of phase shifts in the plague epidemics of colonial India. ( 27791071 )
2016
50
Classic Spotlight: Studies on the Low-Calcium Response of Yersinia pestis Reveal the Secrets of Plague Pathogenesis. ( 27413177 )
2016

Variations for Plague

Expression for Plague

Search GEO for disease gene expression data for Plague.

Pathways for Plague

Pathways related to Plague according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.31 DDX58 MYD88 PLG TLR9
2 11.95 DDX58 MYD88 PECAM1 TLR9
3 11.59 CD86 PECAM1 SELE
4 10.68 MYD88 SELE TLR9
5 10.61 MYD88 PECAM1 SELE TLR9

GO Terms for Plague

Cellular components related to Plague according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 CCR5 CD83 CD86 PECAM1

Biological processes related to Plague according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.78 CD86 DDX58 MYD88 TLR9
2 viral process GO:0016032 9.71 CCR5 CD86 CDC25C DDX58
3 response to lipopolysaccharide GO:0032496 9.7 CD86 MYD88 SELE
4 inflammatory response GO:0006954 9.62 CCR5 MYD88 SELE TLR9
5 response to interleukin-1 GO:0070555 9.51 MYD88 SELE
6 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.49 MYD88 TLR9
7 positive regulation of interleukin-8 production GO:0032757 9.46 DDX58 TLR9
8 positive regulation of interferon-beta production GO:0032728 9.43 DDX58 TLR9
9 positive regulation of interleukin-10 production GO:0032733 9.37 CD83 TLR9
10 toll-like receptor 9 signaling pathway GO:0034162 9.26 MYD88 TLR9
11 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.16 DDX58 TLR9
12 positive regulation of interleukin-6 production GO:0032755 9.13 DDX58 MYD88 TLR9
13 toll-like receptor signaling pathway GO:0002224 8.8 CD86 MYD88 TLR9

Molecular functions related to Plague according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 coreceptor activity GO:0015026 8.96 CCR5 CD86
2 interleukin-1 receptor binding GO:0005149 8.62 MYD88 TLR9

Sources for Plague

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....